Join the Bleeding Disorders Foundation of North Carolina and Novo Nordisk for a night out in Greensboro! In addition to a delicious meal, attendees will hear from Novo Nordisk’s Bradley Odac on their newest product, Alhemo® (concizumab-mtci). Alhemo is the first prefilled, subcutaneous pen for people who have hemophilia A or B with Inhibitors. Alhemo is used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older.

While the topic is specific to hemophilia, this evening is all about bringing our community together regardless of their bleeding disorder—we hope to see you there!